Key result
Pegylated liposomal doxorubicin is an appealing treatment option for elderly breast cancer patients due to its efficacy and safety profile, particularly its rare cardiac toxicity.
Why the study?
Does pegylated liposomal doxorubicin reduce cardiotoxicity while maintaining efficacy compared to conventional doxorubicin in elderly patients with metastatic breast cancer?
Does pegylated liposomal doxorubicin reduce cardiotoxicity while maintaining efficacy compared to conventional doxorubicin in elderly patients with metastatic breast cancer?
Pegylated liposomal doxorubicin is an effective and well-tolerated treatment option for elderly patients with metastatic breast cancer, offering a favorable cardiac safety profile.
Answers are grounded in this paper and cite their sources.
May support use in elderly metastatic breast cancer to limit cardiotoxicity; leaves open need for randomized confirmation.
Breast cancer incidence is increasing among elderly patients. Age is a risk factor for toxicity after chemotherapy for breast cancer. In particular, anthracycline-induced cardiac toxicity is increased in elderly patients. Novel liposomal anthracyclines are associated with less cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is active in breast cancer patients and, has shown comparable efficacy to conventional doxorubicin in clinical trials. Most toxicities during PLD treatment are hematological and mucocutaneous (in particular stomatitis and palmo-plantar erythrodysesthesia), and cardiac toxicity is rare. Tolerability of this agent in elderly patients has been confirmed by clinical trials in the advanced disease. Due to its efficacy and safety profile, PLD is an appealing treatment option for elderly breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Minisini et al. (2008) conducted a review in Metastatic breast cancer in elderly patients. Pegylated liposomal doxorubicin (PLD) vs. Conventional doxorubicin was evaluated. Pegylated liposomal doxorubicin is an appealing treatment option for elderly breast cancer patients due to its efficacy and safety profile, particularly its rare cardiac toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: